IL-1 inhibition in systemic juvenile idiopathic arthritis

Frontiers in Pharmacology

Volumn 7, Issue DEC, 2016, Pages

  Giancane, Gabriella ^a,b   Minoia, Francesca ^a   Davì, Sergio ^a   Bracciolini, Giulia ^a   Consolaro, Alessandro ^a,b   Ravelli, Angelo ^a,b  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Anakinra; Canakinumab; IL1 inhibitors; Rilonacept; Systemic juvenile idiopathic arthritis

Indexed keywords

ANAKINRA; CANAKINUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FERRITIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PLACEBO; PREDNISONE; RILONACEPT;

BONE MARROW BIOPSY; CLINICAL FEATURE; DISEASE DURATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FERRITIN BLOOD LEVEL; HIP RADIOGRAPHY; HUMAN; INFECTION; NEUTROPHIL COUNT; ONSET AGE; PATHOGENESIS; REVIEW; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; UNSPECIFIED SIDE EFFECT;

EID: 85009183683     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00467     Document Type: Review

References (50)

1. Behrens, E. M., Beukelman, T., Gallo, L., Spangler, J., Rosenkranz, M., Arkachaisri, T., et al. (2008). Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J. Rheumatol. 35, 343-348.
2. Behrens, E. M., Beukelman, T., Paessler, M., and Cron, R. Q. (2007). Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J. Rheumatol. 34, 1133-1138.
3. Beukelman, T. (2014). Treatment advances in systemic juvenile idiopathic arthritis. F1000Prime Rep. 6:21. doi: 10.12703/p6-21.
4. Bleesing, J., Prada, A., Siegel, D. M., Villanueva, J., Olson, J., Ilowite, N. T., et al. (2007). The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 56, 965-971. doi: 10.1002/art.22416.
5. Buckland, J. (2013). Paediatric rheumatology: biologic therapy for systemic juvenile idiopathic arthritis-times they are a'changing! Nat. Rev. Rheumatol. 9, 63. doi: 10.1038/nrrheum.2013.2.
6. Canna, S., Frankovich, J., Higgins, G., Narkewicz, M. R., Nash, S. R., Hollister, J. R., et al. (2009). Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist. Pediatr. Rheumatol. 7:21. doi: 10.1186/1546-0096-7-21.
7. de Benedetti, F., and Martini, A. (2005). Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum. 52, 687-693. doi: 10.1002/art.20946.
8. De Benedetti, F., and Schneider, R. (2016). "Systemic juvenile idiopathic arthritis," in Textbook of Pediatric Rheumatology, 7th Edn., eds R. E. Petty, R. M. Laxer, C. B. Lindsley, and L. R. Wedderburn (Philadelphia, PA: Elsevier), 205-216.
9. De Benedetti, F., Brunner, H. I., Ruperto, N., Kenwright, A., Wright, S., Calvo, I., et al. (2012). Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N.Engl. J. Med. 367, 2385-2395. doi: 10.1056/nejmoa1112802.
10. Gattorno, M., Piccini, A., Lasigliè, D., Tassi, S., Brisca, G., Carta, S., et al. (2008). The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58, 1505-1515. doi: 10.1002/art.23437.
11. Giannini, E. H., Ilowite, N. T., Lovell, D. J., Wallace, C. A., Rabinovich, C. E., Reiff, A., et al. (2009). Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 60, 2794-2804. doi: 10.1002/art.24777.
12. Grom, A. A., and Mellins, E. D. (2010). Macrophage activation syndrome: advances towards understanding pathogenesis. Curr. Opin. Rheumatol. 22, 561-566. doi: 10.1097/01.bor.0000381996.69261.71.
13. Grom, A. A., Horne, A., and De Benedetti, F. (2016). Macrophage activation syndrome in the era of biologic therapy. Nat. Rev. Rheumatol. 12, 259-268. doi: 10.1038/nrrheum.2015.179.
14. Horneff, G., Schmeling, H., Biedermann, T., Foeldvari, I., Ganser, G., Girschick, H. J., et al. (2004). The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann. Rheum. Dis. 63, 1638-1644. doi: 10.1136/ard.2003.014886.
15. Ilowite, N. T., Prather, K., Lokhnygina, Y., Schanberg, L. E., Elder, M., Milojevic, D., et al. (2014). Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheum. 66, 2570-2579. doi: 10.1002/art.38699.
16. Kimura, Y., Pinho, P., Walco, G., Higgins, G., Hummell, D., Szer, I., et al. (2005). Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 32, 935-942.
17. Lequerré, T., Quartier, P., Rosellini, D., Alaoui, F., De Bandt, M., Mejjad, O., et al. (2008). Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 67, 302-308. doi: 10.1136/ard.2007.076034.
18. Lovell, D. J., Giannini, E. H., Reiff, A. O., Kimura, Y., Li, S., Hashkes, P. J., et al. (2013). Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 65, 2486-2496. doi: 10.1002/art.38042.
19. Lovell, D. J., Reiff, A., Ilowite, N. T., Wallace, C. A., Chon, Y., Lin, S.-L., et al. (2008). Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 58, 1496-1504. doi: 10.1002/art.23427.
20. Martini, A. (2012a). Systemic juvenile idiopathic arthritis. Autoimmun. Rev. 12, 56-59. doi: 10.1016/j.autrev.2012.07.022.
21. Martini, A. (2012b). It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Ann. Rheum. Dis. 71, 1437-1439. doi: 10.1136/annrheumdis-2012-201388.
22. Martini, G., Biscaro, F., Boscaro, E., Calabrese, F., Lunardi, F., Facco, M., et al. (2015). Reduced levels of circulating progenitor cells in juvenile idiopathic arthritis are counteracted by anti TNF-α therapy. BMC Musculoskelet. Disord. 16:103. doi: 10.1186/s12891-015-0555-9.
23. Masters, S. L., Simon, A., Aksentijevich, I., and Kastner, D. L. (2009). Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu. Rev. Immunol. 27, 621-668. doi: 10.1146/annurev.immunol.25.022106.141627.
24. Mellins, E. D., Macaubas, C., and Grom, A. A. (2011). Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat. Rev. Rheumatol. 7, 416-426. doi: 10.1038/nrrheum.2011.68.
25. Minoia, F., Davì, S., Horne, A., Bovis, F., Demirkaya, E., Akikusa, J., et al. (2015). Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J. Rheumatol. 42, 994-1001. doi: 10.3899/jrheum.141261.
26. Minoia, F., Davì, S., Horne, A., Demirkaya, E., Bovis, F., Li, C., et al. (2014). Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheum. 66, 3160-3169. doi: 10.1002/art.38802.
27. Nigrovic, P. A., Mannion, M., Prince, F. H. M., Zeft, A., Rabinovich, C. E., Van Rossum, M. A. J., et al. (2011). Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 63, 545-555. doi: 10.1002/art.30128.
28. Nigrovic, P. A. (2014). Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheum. 66, 1405-1413. doi: 10.1002/art.38615.
29. Ohlsson, V., Baildam, E., Foster, H., Jandial, S., Pain, C., Strike, H., et al. (2008). Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology 47, 555-556. doi: 10.1093/rheumatology/ken030.
30. Pardeo, M., Pires Marafon, D., Insalaco, A., Bracaglia, C., Nicolai, R., Messia, V., et al. (2015). Anakinra in systemic juvenile idiopathic arthritis: a single-center experience. J. Rheumatol. 42, 1523-1527. doi: 10.3899/jrheum.141567.
31. Pascual, V., Allantaz, F., Arce, E., Punaro, M., and Banchereau, J. (2005). Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201, 1479-1486. doi: 10.1084/jem.20050473.
32. Petty, R. E., Southwood, T. R., Manners, P., Baum, J., Glass, D. N., Goldenberg, J., et al. (2004). International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 31, 390-392.
33. Quartier, P., Allantaz, F., Cimaz, R., Pillet, P., Messiaen, C., Bardin, C., et al. (2011). A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 70, 747-754. doi: 10.1136/ard.2010.134254.
34. Quartier, P., Taupin, P., Bourdeaut, F., Lemelle, I., Pillet, P., Bost, M., et al. (2003). Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 48, 1093-1101. doi: 10.1002/art.10885.
35. Ravelli, A., Grom, A. A., Behrens, E. M., and Cron, R. Q. (2012). Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 13, 289-298. doi: 10.1038/gene.2012.3.
36. Ravelli, A., Minoia, F., Davì, S., Horne, A., Bovis, F., Pistorio, A., et al. (2015). Development and initial validation of classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 12(Suppl 1).
37. Ravelli, A., Minoia, F., Davì, S., Horne, A., Bovis, F., Pistorio, A., et al. (2016). 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism/American college of rheumatology/paediatric rheumatology international trials organisation collaborative initiative. Ann. Rheum. Dis. 68, 566-576. doi: 10.1002/art.39332.
38. Ravelli, A. (2002). Macrophage activation syndrome. Curr. Opin. Rheumatol. 14, 548-552. doi: 10.1097/00002281-200209000-00012.
39. Ruperto, N., Brunner, H. I., Quartier, P., Constantin, T., Wulffraat, N., Horneff, G., et al. (2012). Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N.Engl. J. Med. 367, 2396-2406. doi: 10.1056/nejmoa1205099.
40. Ruperto, N., Lovell, D. J., Quartier, P., Paz, E., Rubio-Perez, N., Silva, C. A., et al. (2010). Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 62, 1792-1802. doi: 10.1002/art.27431.
41. Sandborg, C., and Mellins, E. D. (2012). A new era in the treatment of systemic juvenile idiopathic arthritis. N.Engl. J. Med. 367, 2439-2440. doi: 10.1056/nejme1212640.
42. Shimizu, M., Nakagishi, Y., and Yachie, A. (2013). Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine 61, 345-348. doi: 10.1016/j.cyto.2012.11.025.
43. Solari, N., Palmisani, E., Consolaro, A., Pistorio, A., Viola, S., Buoncompagni, A., et al. (2013). Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. J. Rheumatol. 40, 192-200. doi: 10.3899/jrheum.120842.
44. Swart, J. F., Barug, D., Möhlmann, M., and Wulffraat, N. M. (2010). The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. Expert Opin. Biol. Ther. 10, 1743-1752. doi: 10.1517/14712598.2010.532785.
45. Vastert, S. J., de Jager, W., Noordman, B. J., Holzinger, D., Kuis, W., Prakken, B. J., et al. (2014). Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 66, 1034-1043. doi: 10.1002/art.38296.
46. Vastert, S. J., Kuis, W., and Grom, A. A. (2009). Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract. Res. Clin. Rheumatol. 23, 655-664. doi: 10.1016/j.berh.2009.08.003.
47. Verbsky, J. W., and White, A. J. (2004). Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 31, 2071-2075.
48. Yamaguchi, M., Ohta, A., Tsunematsu, T., Kasukawa, R., Mizushima, Y., Kashiwagi, H., et al. (1992). Preliminary criteria for classification of adult Still's disease. J. Rheumatol. 19, 424-430.
49. Yokota, S., Tanaka, T., and Kishimoto, T. (2012). Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther. Adv. Musculoskelet. Dis. 4, 387-397. doi: 10.1177/1759720X12455960.
50. Zeft, A., Hollister, R., LaFleur, B., Sampath, P., Soep, J., McNally, B., et al. (2009). Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J. Clin. Rheumatol. 15, 161-164. doi: 10.1097/rhu.0b013e3181a4f459.